Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review
Background We aimed to determine the risk of recurrence for symptomatic venous
thromboembolism (VTE) provoked by different transient risk factors. Data Sources MEDLINE …
thromboembolism (VTE) provoked by different transient risk factors. Data Sources MEDLINE …
Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism
M Verhovsek, JD Douketis, Q Yi… - Annals of internal …, 2008 - acpjournals.org
Background: The optimal duration of anticoagulation for a first episode of unprovoked
venous thromboembolism (VTE) is uncertain. Methods for predicting risk for recurrence may …
venous thromboembolism (VTE) is uncertain. Methods for predicting risk for recurrence may …
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
Background Haematoma expansion is a major cause of mortality in intracranial
haemorrhage related to vitamin K antagonists (VKA-ICH). Normalisation of the international …
haemorrhage related to vitamin K antagonists (VKA-ICH). Normalisation of the international …
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial
Background Although practice guidelines recommend outpatient care for selected,
haemodynamically stable patients with pulmonary embolism, most treatment is presently …
haemodynamically stable patients with pulmonary embolism, most treatment is presently …
The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial
MI Covas, K Nyyssönen, HE Poulsen… - Annals of internal …, 2006 - acpjournals.org
Background: Virgin olive oils are richer in phenolic content than refined olive oil. Small,
randomized, crossover, controlled trials on the antioxidant effect of phenolic compounds …
randomized, crossover, controlled trials on the antioxidant effect of phenolic compounds …
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation …
W Mueck, AWA Lensing, G Agnelli, H Decousus… - Clinical …, 2011 - Springer
Abstract Background and Objective: Rivaroxaban is an oral, direct Factor Xa inhibitor, which
is at an advanced stage of clinical development for prevention and treatment of …
is at an advanced stage of clinical development for prevention and treatment of …
Prospective validation of the pulmonary embolism severity index
Practice guidelines recommend outpatient care for selected patients with non-massive
pulmonary embolism (PE), but fail to specify how these low-risk patients should be identified …
pulmonary embolism (PE), but fail to specify how these low-risk patients should be identified …
Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American …
A Qaseem, V Snow, P Barry, ER Hornbake… - Annals of internal …, 2007 - acpjournals.org
This guideline summarizes the current approaches for the diagnosis of venous
thromboembolism. The importance of early diagnosis to prevent mortality and morbidity …
thromboembolism. The importance of early diagnosis to prevent mortality and morbidity …
The genetics of venous thromboembolism
R Gohil, G Peck, P Sharma - Thrombosis and haemostasis, 2009 - thieme-connect.com
We conducted a systematic and comprehensive meta-analysis on all candidate genes to
assess their genetic contribution to the aetiology of venous thromboembolism …
assess their genetic contribution to the aetiology of venous thromboembolism …
Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked …
This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Background: In patients with a first unprovoked venous thromboembolism …
supplement. Background: In patients with a first unprovoked venous thromboembolism …